Josephine D. Kahn

Internal Medicine
75 Francis St # B-4
Boston, MA 02115

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Conditional activation of IL-12 through a Fibronectin-EDB dependent switch gate.

Conditional activation of IL-12 through a Fibronectin-EDB dependent switch gate.

Journal: mAbs
Published: July 23, 2026

Cutting to the Chase.

Cutting to the Chase.

Journal: The New England journal of medicine
Published: May 27, 2026

Identification of small molecule inhibitors of PPM1D using an integrated drug discovery platform.

Identification of small molecule inhibitors of PPM1D using an integrated drug discovery platform.

Journal: iScience
Published: June 25, 2024

Identification of Small Molecule Inhibitors of PPM1D Using a Novel Drug Discovery Platform.

Identification of Small Molecule Inhibitors of PPM1D Using a Novel Drug Discovery Platform.

Journal: bioRxiv : the preprint server for biology
Published: June 03, 2024

PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy.

PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy.

Journal: Blood
Published: March 02, 2023

Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state.

Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state.

Journal: Nature communications
Published: October 06, 2021

PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells.

PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells.

Journal: Blood
Published: May 11, 2018

SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia.

SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia.

Journal: Blood
Published: March 24, 2017

Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes.

Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes.

Journal: Haematologica
Published: March 10, 2015
Showing 1-9 of 9

Last Updated: 09/26/2026